文献速递胸部肿瘤头颈与中枢神经肿瘤

POU2F3在小细胞肺癌中的临床病理及基因组分析:聚焦其在神经内分泌标志物低表达小细胞肺癌中的诊断价值

POU2F3 in SCLC: Clinicopathologic and Genomic Analysis With a Focus on Its Diagnostic Utility in Neuroendocrine-Low SCLC.
PubMed 文献 · J Thorac Oncol · 2022-06-24

该研究筛查254例小细胞肺癌(SCLC)中POU2F3表达,分析阳性肿瘤的临床病理及基因组特征,并探索其他肺癌类型中的表达。POU2F3在12%的SCLC中表达,与标准神经内分泌标志物低表达强相关,在神经内分泌标志物完全阴性或极低表达的SCLC中75%表达,有助于诊断。SCLC-P富集PTEN失活、MYC扩增和20q13扩增。

要点

  • POU2F3在12%(30/254)的SCLC中表达,与神经内分泌标志物低表达强相关。
  • 在神经内分泌标志物完全阴性或极低表达的SCLC中,75%(15/20)表达POU2F3,有助于诊断。
  • SCLC-P富集PTEN失活、MYC扩增和20q13扩增,RB1和TP53改变率与其他SCLC相似。

核心结论

  • 这是迄今最大的SCLC-P临床样本队列,描述了POU2F3在神经内分泌标志物低表达或缺失的挑战性SCLC亚群中的诊断价值。
  • SCLC-P的独特基因组改变可能提供新的治疗靶向途径。
  • POU2F3在少数其他肺癌类型中的作用需进一步研究。

研究设计与样本

  • 研究筛查了254例SCLC的POU2F3表达,并综合分析POU2F3阳性肿瘤的组织病理学、基因组和临床特征。
  • 研究还探索了其他主要肺癌类型(n=433)和一组潜在的SCLC诊断模仿者(n=123)中的POU2F3表达。

主要发现

  • POU2F3在30/254(12%)的SCLC中表达,与突触素、嗜铬粒蛋白A、CD56、INSM1低表达强相关。
  • 在神经内分泌标志物完全阴性或极低表达的SCLC中,POU2F3表达率为75%(15/20),有助于支持诊断。
  • 靶向二代测序显示,SCLC-P(n=12)富集PTEN失活、MYC扩增和20q13扩增,但RB1和TP53改变率与其他SCLC(n=155)相似。
  • 在SCLC之外,POU2F3表达仅见于大细胞神经内分泌癌(12%)和基底样鳞状细胞癌(22%)。

局限性

  • POU2F3在少数其他肺癌类型中的作用需进一步研究。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: POU2F3 is a recent marker of a small cell lung carcinoma (SCLC) subtype related to chemosensory tuft cells (SCLC-P). The characteristics of SCLC-P have not been fully defined, and the data on POU2F3 expression in other lung tumors are scarce. METHODS: We screened 254 SCLC for POU2F3 expression and comprehensively analyzed histopathologic, genomic, and clinical characteristics of POU2F3-positive tumors. We also explored POU2F3 expression in other major lung cancer types (n = 433) and a targeted set of potential diagnostic mimics of SCLC (n = 123). RESULTS: POU2F3 was expressed in 30 of 254 (12%) SCLC and was strongly associated with low expression of standard neuroendocrine markers (synaptophysin, chromogranin A, CD56, INSM1). Notably, POU2F3 was expressed in 75% of SCLC with entirely negative or minimal neuroendocrine marker expression (15/20) and was helpful in supporting the diagnosis of SCLC in such cases. Broad targeted next-generation sequencing revealed that SCLC-P (n = 12) exhibited enrichment in several alterations, including PTEN inactivation, MYC amplifications, and 20q13 amplifications, but similar rates of RB1 and TP53 alterations as other SCLC (n = 155). Beyond SCLC, POU2F3 expression was exclusively limited to large cell neuroendocrine carcinoma (12%) and basaloid squamous cell carcinoma (22%). CONCLUSIONS: This is the largest cohort of SCLC-P clinical samples to date, where we describe the diagnostic utility of POU2F3 in a challenging subset of SCLC with low or absent expression of standard neuroendocrine markers. The distinct genomic alterations in SCLC-P may offer a novel avenue for therapeutic targeting. The role of POU2F3 in a narrow subset of other lung cancer types warrants further study.

来源:J Thorac Oncol,查看原文。版权归原作者所有。

引用

  1. Baine MK, Febres-Aldana CA, Chang JC, et al. POU2F3 in SCLC: Clinicopathologic and Genomic Analysis With a Focus on Its Diagnostic Utility in Neuroendocrine-Low SCLC. J Thorac Oncol. 2022. PMID: 35760287. doi:10.1016/j.jtho.2022.06.004

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。